TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370588
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Saline infusion during same time period.
Study: NCT04008004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EDP-514
Study: NCT02225288
Drug: E2022
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
Study: NCT01071317
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg PO bid prn headache
Study: NCT00545909
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 6 months (+ feedback)
Study: NCT00545909
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 6 months (- feedback)
Study: NCT04952207
Drug: Direct-acting antiviral agents
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
Study: NCT01897571
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
Study: NCT01697956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Study: NCT00939211
Drug: AZD9164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for inhalation through nebulization, single dose
Study: NCT00939211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00966706
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given systemically
Study: NCT00874393
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine
Study: NCT00874393
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone
Study: NCT00874393
Drug: Infusion Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (D5W)
Study: NCT00603278
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW685698X
Study: NCT00603278
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01779089
Drug: Minocycline 100 mg po bid for 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg po bid or placebo for 6 months
Study: NCT01779089
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428622
Drug: BI54903
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethanolic solution
Study: NCT01786915
Drug: Bendavia 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01786915
Drug: Bendavia 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01786915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00959634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose administered twice daily on Study Days 1-10
Study: NCT03258034
Drug: SPA
Normalized name: TSPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
Study: NCT06212596
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
Study: NCT03715634
Drug: INDV-6200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
Study: NCT03715634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
Study: NCT00157105
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02312245
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02548585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously.
Study: NCT00397098
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00805441
Drug: LY686017
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 milligrams (mg) daily by oral route for 12 weeks
Study: NCT00805441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily by oral route for 12 weeks
Study: NCT00141271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
Study: NCT04917315
Drug: JLP-2002 A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
Study: NCT04917315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
Study: NCT01720407
Drug: Placebo + surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
Study: NCT02026583
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04321096
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00768716
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg by mouth once
Study: NCT05361083
Drug: F18CETO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of F18CETO or O15water followed by PET/CT
Study: NCT01391338
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01391338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02717780
Drug: Fentanyl and sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02717780
Drug: Remifentanil and desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00547716
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00555620
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Study: NCT01289899
Drug: BR-A-657
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120, 360mg or placebo 7days
Study: NCT02462720
Drug: Varithena®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varithena® treatment in accordance with full prescribing information and instructions for use
Study: NCT02187120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00965393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic infusion of placebo (saline)
Study: NCT01345253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Study: NCT01816165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
Study: NCT01560962
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01560962
Drug: tobramycin-dexmethasone
Normalized name: dexamethasone / tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02454647
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00582855
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00582855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03663049
Drug: discontinue statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue statin as prescribed for 12 weeks
Study: NCT02331771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
Study: NCT00003376
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003376
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01476137
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor
Study: NCT01476137
Drug: GSK2110183
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitor
Study: NCT01684345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00648271
Drug: Lopressor® Tablets 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x50mg, single dose fed
Study: NCT00083148
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01809444
Drug: Prednisone+placebo of Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
Study: NCT01809444
Drug: Doxycycline+placebo of Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
Study: NCT02199444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00202228
Drug: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
Study: NCT03044756
Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Study: NCT02069379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules prepared identically to Metformin capsules
Study: NCT04113187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os, twice a day (morning and evening) during three months
Study: NCT00801905
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Study: NCT00014508
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02869308
Drug: stannous pyrophosphate
Normalized name: Technetium (99m-Tc) stannous pyrophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1ml Angiocis
Study: NCT00561678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
Study: NCT01862224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily (Week 0 to Week 12).
Study: NCT01862224
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
Study: NCT00330135
Drug: placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection - 1 injection
Study: NCT00434642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Study: NCT00427544
Drug: PRA-027
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00244751
Drug: GI262570 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI262570 0.5 mg
Study: NCT00244751
Drug: GI262570 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI262570 1.0 mg
Study: NCT00244751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02785822
Drug: hMG-HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian stimulation with hMG-HP (150 IU / day)
Study: NCT01879488
Drug: technetium-99m - Diethylenetriaminepentaacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00135226
Drug: Placebo Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01442766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
Study: NCT01727193
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
Study: NCT04325737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
Study: NCT01375582
Drug: B & L Soothe Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Drop
Study: NCT00882323
Drug: Cyclophosphamide, Fludarabine, Thymoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)
Study: NCT02649478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02649478
Drug: Advair Diskus 100/50
Normalized name: Advair Diskus 100/50 Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Study: NCT04520620
Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe
Normalized name: Lovenox 40 MG in 0.4 mL Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours
Study: NCT04035733
Drug: rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
Study: NCT03022747
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6-mercaptopurine and methotrexate
Study: NCT01738087
Drug: NEXThaler 100/6 mcg DPI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00346242
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02954276
Drug: Imitrex Oral Product
Normalized name: Imitrex Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg
Study: NCT01656512
Drug: zolendronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg.
Study: NCT01034774
Drug: ACHN-490 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
Study: NCT00003996
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02420847
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00474409
Drug: Merislon
Normalized name: Merilog
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02108496
Drug: NSAID's and Non-surgical Treatment Options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Study: NCT02108496
Drug: Intra-Articular Injections with Corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Study: NCT01872260
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
Study: NCT01225289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day for six months
Study: NCT02254122
Drug: BEA 2180 BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03430362
Drug: Hyoscine N Butylbromide
Normalized name: Hyoscine N butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
Study: NCT03430362
Drug: Normal Saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B, will receive 2 ml of normal saline single intravenous dose
Study: NCT01490047
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion over 60 minutes
Study: NCT02619578
Drug: propofol, remifentanil, vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
Study: NCT00021996
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01177644
Drug: PDS 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03063983
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous oral cyclophosphamide
Study: NCT03063983
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous oral methotrexate
Study: NCT00515879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosage as active pill
Study: NCT03537534
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applying surgilube following endourologic procedure
Study: NCT03586284
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 to 28 days of placebo pill treatment
Study: NCT03586284
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 to 28 days of topical placebo treatment
Study: NCT01612507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 h infusion
Study: NCT01612507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion
Study: NCT00006220
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04057300
Drug: acetylsalicylic acid (ASA) 81mg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid tablet
Study: NCT03062488
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-modal analgesia with IV acetaminophen
Study: NCT03062488
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single modal analgesia
Study: NCT03062488
Drug: PO acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-modal analgesia with PO acetaminophen